---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-032422"
form_type: "8-K"
ticker: "CTNM"
cik: "0001855175"
company_name: "Contineum Therapeutics, Inc."
filed_at: "2025-10-30T23:59:59+00:00"
generated_at: "2026-05-17T01:24:53.800633+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Contineum Therapeutics Q3 net loss $12.8M, cash $182.4M, pipeline milestones affirmed

## Summary
- Cash, cash equivalents and marketable securities $182.4M; projected cash runway extended through 2028.
- Net loss $12.8M vs $10.3M in prior-year quarter; R&D expenses $11.0M (+13% YoY).
- Generated $19.0M from ATM offerings of 3.2M shares at weighted avg $6.04/share.
- Topline data from PIPE-307 Phase 2 VISTA RRMS trial expected Q4 2025; global Phase 2 for PIPE-791 IPF to initiate Q4 2025.
- Deferred initiation of PIPE-791 PrMS and CTX-343 trials to extend cash runway.

## SEC filing metadata
- accession: 0001437749-25-032422
- form_type: 8-K
- ticker: CTNM
- cik: 0001855175
- company_name: Contineum Therapeutics, Inc.
- filed_at: 2025-10-30T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1855175/000143774925032422/0001437749-25-032422-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1855175/000143774925032422/ctnm20251015_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-032422
- JSON: https://secwatch.observer/filing/0001437749-25-032422.json
- Plain text: https://secwatch.observer/filing/0001437749-25-032422.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.